Gena Wang has given his Buy rating due to a combination of factors surrounding Sangamo Biosciences’ promising developments in their Fabry program. The company has recently announced an alignment with ...

Department of Human Genetics, Mount Sinai School of Medicine, Fifth Avenue at 100th Street, New York, NY 10029, USA Tel. +1-212-659-6700; Fax: +1-212-360-1809 e-mail ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

The most notable program advancement would be regarding the fact that the company caught a huge surprise development from the FDA relating to its Fabry Disease treatment program. That is ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

This came after Takeda Biopharmaceuticals presented the proposal for an update in the package insert regarding home infusion ...

“I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

If you have an active lifestyle or are often outdoors, finding a hearing aid that is water resistant can be important. Read our guide for your top options.

An elderly couple sit on a bench in the centre of Trnava, a town about 60 kilometres from Bratislava, smiling as they share ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - U.S. Food and Drug Administration (FDA ...